MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer – Neal Shore, Daniel Spratt, & Alicia Morgans
Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraA [...]
Predicting Response to Hormone Therapy in Prostate Cancer With a Post-Prostatectomy MMAI Model – UroToday
Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a ne [...]
NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification – UroToday
Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence o [...]
Multimodal AI Informing Treatment Decisions in Advanced Prostate Cancer – Gerhardt Attard
Alicia Morgans interviews Gerhardt Attard about groundbreaking research presented at ESMO 2023, utilizing the STAMPEDE data s [...]
The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript
Dan Spratt joins Alicia Morgans in a conversation on the Artera AI multimodal artificial intelligence model manuscript publis [...]
Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers – Paul Nguyen
In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer tr [...]
Artera Multi-Modal AI Platform – Guiding Treatment Decisions in Men with Prostate Cancer – Andre Esteva & Felix Feng
Andre Esteva and Felix Feng join Alicia Morgans to discuss the Artera MMAI platform in prostate cancer intended to identify p [...]
Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model – Jonathan Tward
Jonathan Tward joins Alicia Morgans to discuss advancing prognostic capabilities in prostate cancer risk stratification using [...]
Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer – Daniel Spratt
Alicia Morgans and Daniel Spratt discuss an AI-derived multi-modal digital pathology-based biomarker test designed towards im [...]